Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 17,040

Document Document Title
WO/2009/146033A3
The present invention provides novel genetic modifiers of SMN function. In particular, the present invention provides methods of treating spinal muscular atrophy (SMA) in a subject in need thereof by manipulating specific genes in the BM...  
WO/2009/144278A3
An enriched conglutin-γ protein extract from lupin seeds having a % by weight of conglutin-γ between 10 and 30%, or a conglutin-γ protein, or functional derivatives thereof for use as a medicament, as food integrator or diet supplemen...  
WO/2009/146310A1
This disclosure relates to deuterated Tizanidine, to compositions comprising the compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by- administering ...  
WO/2009/144093A8
Hydroxytyrosol or olive juice containing hydroxytyrosol can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.  
WO/2009/144481A3
A construct comprising a cell delivery peptide covalently attached to a biologically active compound suitable for delivery of said biologically active compound into cells, wherein optionally the cells are cardiac muscle, skeletal muscle,...  
WO/2009/141159A1
Compounds of formula (I): wherein R1, R2, R3, and n are as defined herein, are useful for the treatment or prophylaxis of Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia.  
WO/2009/142195A1
Disclosed is a method for inducing/maintaining remission of an immune disease, which can reduce serious adverse side effects and stress in a patient. After the induction of remission of an immune disease with a biological substance or a ...  
WO/2009/142321A1
The present invention is related to study on synthesis of a novel thiophenediamine derivative having a urea structure and finding of a pharmacological action of the derivative. Specifically, the present invention provides a compound rep...  
WO/2009/139876A2
Muscle tissue regeneration is one of the most important homeostatic processes of adult skeletal muscle, which after development retains the capacity to regenerate in response to different type of stimuli, including a direct trauma or neu...  
WO/2009/140448A8
The present invention provides a compound of the Formula (I), or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; ...  
WO/2009/139361A1
Disclosed is a glucocorticoid receptor agonist composed of a compound represented by formula (1) or a salt thereof, which is a 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative having a substituted oxy group. A novel pharmacologi...  
WO/2009/137880A1
The invention provides a method of treating a disorder characterised by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological disea...  
WO/2009/137879A1
The invention provides a method of treatment of any disorder in which administration of angiogenin is beneficial wherein the angiogenin is administered orally. Particularly, the oral angiogenin does not require a carrier or excipient or ...  
WO/2009/140448A1
The present invention provides a compound of the Formula (I), or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; ...  
WO/2009/133905A1
Disclosed is a pharmaceutical composition for the treatment or prevention of a disease which can be prevented or treated through the inhibition of the activity of human FGF-23 protein. Specifically disclosed is a peptide comprising an am...  
WO/2009/133861A1
Disclosed is a cyclic amine compound useful as an androgen receptor modulator. [In formula (I), R1 represents a hydrogen atom, a halogen atom or the like; R2 represents a hydrogen atom, a halogen atom or the like; R3 represents a heteroc...  
WO/2009/131201A1
Disclosed are: a therapeutic agent for intermittent claudication, which comprises a tricyclic compound represented by formula (I) [wherein R1 represents a substituted or unsubstituted lower alkyl] or a pharmacologically acceptable salt t...  
WO/2009/129501A1
Disclosed herein are compounds, compositions, and methods for enhancing smooth muscle function in a subject by administration of soluble epoxide hydrolase inhibitors and for treating subjects with smooth muscle disorders including erecti...  
WO/2009/128481A1
Disclosed is a glucokinase activator which is useful as a pharmaceutical agent such as a prophylactic/therapeutic agent for diabetes, obesity and others. Specifically disclosed is a compound represented by formula (I) [wherein each symbo...  
WO/2009/128558A1
Disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof, which can be used as an activator for a PPAR. (In the formula, R1 and R2 independently represent a hydrogen atom, an alkyl group h...  
WO/2009/124693A1
The present invention relates to 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4- benzoquinone (idebenone) for treating and/or preventing respiratory illness associated with certain forms of muscular dystrophy.  
WO/2009/126350A2
Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.  
WO/2009/123316A1
Disclosed is an sGC activator, particularly a compound which is useful for the prevention or treatment of diseases including hypertension, ischemic heart diseases, heart failure, kidney diseases, arteriosclerotic diseases, atrial fibrill...  
WO/2009/121623A2
Compounds of formula (I): wherein X, L1, R1, L2, R2, R3, and R4 are as defined herein, are useful in the treatment or prophylaxis of Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia.  
WO/2009/123174A1
A medicinal preparation for patients having a neutralizing antibody against a botulinum toxin originating in a Clostridium botulinum type A1 strain (type A1 botulinum toxin) characterized by comprising as the active ingredient a 150 kDa ...  
WO/2009/121623A3
Compounds of formula (I): wherein X, L1, R1, L2, R2, R3, and R4 are as defined herein, are useful in the treatment or prophylaxis of Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia.  
WO/2009/123221A1
Disclosed is a prophylactic or therapeutic agent for nerve diseases such as ischemic brain diseases and neurodegenerative diseases or the like or a prophylactic or therapeutic agent for diseases for which an antioxidant activity is effec...  
WO/2009/120815A9  
WO/2009/120304A1
Agonists of a non-proteolytically activated thrombin receptor, and more particularly, thrombin peptide derivatives, can be used in methods to cause smooth muscle relaxation. Compositions comprising thrombin peptide derivatives can be adm...  
WO/2009/120815A2  
WO/2009/115321A8
The present invention relates to substituted imidazopyrimidine derivatives, substituted imidazopyrazine derivatives and substituted imidazopyridazine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocorti...  
WO/2009/115321A1
The present invention relates to substituted imidazopyrimidine derivatives, substituted imidazopyrazine derivatives and substituted imidazopyridazine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocorti...  
WO/2009/114597A1
Compositions containing apoaequorin and methods for their use in treating symptoms and disorders related to calcium imbalances associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided...  
WO/2009/105691A3
Methods are provided herein for treatment of myotonic dystrophy and other toxic RNA diseases in a subject. In some examples, the method comprises administration of a compound that binds a nucleotide repeat expansion in a ribonucleic acid...  
WO/2009/104388A1
Disclosed is a prophylactic/therapeutic agent for collagenosis, which can inhibit the function of TREM-1 to exhibit a prophylactic/therapeutic effect on collagenosis. Also disclosed is a method for the screening of a prophylactic/therape...  
WO/2009/104807A1
In one embodiment, provided is a composition comprising a prostaglandin compound for modulating stem cell proliferation and/or differentiation in a mammalian subject. In another embodiment, the instant application is a composition compri...  
WO/2009/105691A2
Methods are provided herein for treatment of myotonic dystrophy and other toxic RNA diseases in a subject. In some examples, the method comprises administration of a compound that binds a nucleotide repeat expansion in a ribonucleic acid...  
WO/2009/101399A1
A method of correcting expression of a gene in a human cell having a muscle disease or muscular dystrophy phenotype, wherein without correction the gene fails to express functional protein due to one or more mutations, said method compri...  
WO/2009/101137A1
We disclose the use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well a...  
WO/2009/099326A1
The current invention provides for methods and medicaments that apply an oligonucleotide comprising aninosine and/or an uracile and/or a nucleotide containing a base able to form a wobble base pair, said oligonucleotide being preferably ...  
WO/2009/098533A1
The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.  
WO/2009/098577A2
The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.  
WO/2009/098577A3
The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.  
WO/2009/095378A1
The invention provides methods for the diagnosis and treatment of musculoskeletal disorders relating to the Hedgehog pathway, including but not limited to muscular dystrophy (e.g., Duchenne Muscular Dystrophy) using agents that agonize S...  
WO/2009/079741A1
Mammalian cells express heat shock proteins (HSPs) in response to various stresses, such as exercise. Recent studies suggest that expression of heat shock proteins in general, and HSP72 in particular, play a role in muscular hypertrophy....  
WO/2009/079562A2
The present invention relates to compositions and methods for treating and preventing skeletal muscle deficiencies. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188 - P188) and methods...  
WO/2009/079562A3
The present invention relates to compositions and methods for treating and preventing skeletal muscle deficiencies. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188 - P188) and methods...  
WO/2009/073944A1
Disclosed is the use of pyridoxine α-hydroxyisocaproate for attenuating metabolic acidosis and decreasing ammonia accumulation in blood and muscle. As a result of this action, there is a reduction in central and muscular fatigue and a d...  
WO/2009/073947A1
The present invention relates to stable salts of β -alanine and an organic acid selected from the group consisting of malate, citrate and fumarate, endowed with enhanced nutritional and/or therapeutical efficacy in respect to their indi...  
WO/2009/073942A1
A nutritional composition comprising at least an effective amount of trigonelline or derivative of trigonelline and an effective amount of tropane alkaloids, wherein the ingredients act substantially simultaneously improve the consistenc...  

Matches 701 - 750 out of 17,040